CJC-1295 (no DAC) vs Ipamorelin
Both CJC-1295 (no DAC) and Ipamorelin are used for growth-hormone and anti-aging. Here's how their evidence, dosing, and regulatory status actually compare.
CJC-1295 (no DAC)
Evidence BModified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
View full CJC-1295 (no DAC) profile →Ipamorelin
Evidence BIpamorelin Acetate
A selective growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin. The safest GH peptide with the fewest side effects.
View full Ipamorelin profile →Side-by-Side
| Attribute | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — Category 1 (compounding allowed) |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 100–300 mcg before bed (subcutaneous) |
| Clinics Indexed | 156 | 195 |
| Categories | growth-hormone, anti-aging, recovery | growth-hormone, anti-aging |
Key reported benefits — CJC-1295 (no DAC)
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Key reported benefits — Ipamorelin
- ✓Clean GH release
- ✓Improved sleep quality
- ✓Fat reduction
- ✓Joint health
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.